A Phase 1/2 interventional study of Atezolizumab and Enfortumab Vedotin in Urothelial Carcinoma and Bladder Cancer, sponsored by Hoffmann-La Roche. Terminated at 33 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell — 10 open to participants now, 15 under way, 1 of them phase 3. enfortumab vedotin · Carcinoma, Transitional Cell.
Among the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 4 in phase 1/2, and was the 4th registered.
632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →10 of the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell are open now, in 6 countries. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States, Canada, Korea, Republic of and 1 more country
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
University of Oklahoma · Sites in United States
Ages 18+
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
enfortumab vedotin: first FDA approval 2019 (PADCEV), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, enfortumab vedotin is the treatment under test here. Read study by study →
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 14 · Phase 3 1 · Phase 4 1
First in 2017; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 272 is above the median of 50 across 499 interventional studies indexed under Carcinoma, Transitional Cell.
Median enrollment 49 across the 20 interventional studies. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
12 studies in Carcinoma, Transitional Cell by Hoffmann-La Roche: none open now, 1 under way, none of them phase 3. Of 10 finished, 4 (40%) have results posted.
Among the 12 studies in Carcinoma, Transitional Cell by Hoffmann-La Roche, this one is one of 2 that started in 2019, is the only one in phase 1/2, and was the 10th registered.
Hoffmann-La Roche’s Carcinoma, Transitional Cell studies by the year they started, since 2015.
6 of the studies testing enfortumab vedotin in Carcinoma, Transitional Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04963153National Cancer Institute (NCI)Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | 2026-12-01 |
| NCT06862219Astellas Pharma Global Development, Inc.A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer | 2026-12-31 |
| NCT04724018Dana-Farber Cancer InstituteSacituzumab Govitecan Plus EV in Metastatic UC | 2027-02-01 |
| NCT07647289Peking University Third HospitalEV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC | 2027-04 |
| NCT05239624Memorial Sloan Kettering Cancer CenterEnfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, from their registry updates:
Among Hoffmann-La Roche’s 12 in Carcinoma, Transitional Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with MIBC and in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population (e.g., with regard to prior anti-cancer treatment or biomarker status). Participants in the mUC Cohort who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen for Stage 2.
Inclusion Criteria for mUC Cohort:
Inclusion Criteria for MIBC Cohorts:
Exclusion Criteria for mUC Cohort:
Exclusion for MIBC Cohorts:
Additional Exclusion Criteria for Atezo+Tira and Atezo (Atezolizumab) +Tira+Cis (Cisplatin)+Gem (Gemcitabine) in the MIBC Cohorts:
- Active Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection at screening.
Additional Exclusion Criteria for the Cisplatin-Eligible MIBC Cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
Drug: Atezolizumab
Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
Drug: Atezolizumab · Drug: Enfortumab Vedotin
Participants will receive atezolizumab and Niraparib (Nira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
Drug: Atezolizumab · Drug: Niraparib
Participants will receive atezolizumab and magrolimab (Hu5F9-G4) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
Drug: Atezolizumab · Drug: Magrolimab (Hu5F9-G4)
Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
Drug: Atezolizumab · Drug: Tiragolumab
Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
Drug: Atezolizumab · Drug: Sacituzumab Govitecan
Participants will receive atezolizumab and Tocilizumab (TCZ) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
Drug: Atezolizumab · Drug: Tocilizumab
Participants will receive atezolizumab and RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
Drug: Atezolizumab
Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
Drug: Atezolizumab · Drug: Enfortumab Vedotin
Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
Drug: Atezolizumab · Drug: Sacituzumab Govitecan
Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.
Drug: Atezolizumab
Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.
Drug: Atezolizumab · Drug: Tiragolumab
Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.
Drug: Atezolizumab
Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.
Drug: Atezolizumab · Drug: Tiragolumab
Participants will receive 3 cycles of Atezolizumab, Cisplatin, and Gemcitabine pre-surgery and 14 cycles of Atezolizumab only post-surgery.
Drug: Atezolizumab · Drug: Cisplatin · Drug: Gemcitabine
Participants will receive Atezolizumab, Tiragolumab (Tira), Cisplatin and Gemcitabine for 3 cycles pre-surgery and 14 cycles of Atezolizumab and Tiragolumab (Tira) post-surgery.
Drug: Atezolizumab · Drug: Tiragolumab · Drug: Cisplatin · Drug: Gemcitabine
For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle. For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.
Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.
Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.
Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.
Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.
Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
Stage 1 mUC Cohorts: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with an objective response (OR), characterized by a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart during Stage 1, as determined by the investigator per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). CR was defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.
Time frame: Up to 61.5 months
MIBC Cohorts: Pathological Complete Response (pCR)
pCR was defined as the percentage of participants with an absence of residual invasive cancer of the complete resected specimen. Percentages have been rounded off.
Time frame: Up to 17.8 months
Stage 1 mUC Cohorts: Progression-free Survival (PFS) After Randomization
PFS after randomization was defined as the time from randomization to the first occurrence of disease progression (PD) or death from any cause, whichever occurred first in Stage 1, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. PFS for participants with no documented PD or death was censored at the day of the last tumor assessment. Kaplan-Meier (K-M) method was used to estimate the median PFS.
Time frame: From randomization to PD or death from any cause, whichever occurred first (up to 62 months)
Stage 1 mUC Cohorts: Overall Survival (OS) After Randomization
OS after randomization was defined as the time from randomization to death from any cause. Data for participants who had not died were censored at the last date they were known to be alive. K-M method was used to estimate the median OS.
Time frame: From randomization to death from any cause (up to 69.1 months)
Stage 1 mUC Cohorts: OS Rate at Month 12
OS rate at Month 12 was defined as percentage of participants who did not experience death from any cause at the specified timepoint. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate OS rate. Percentages have been rounded off.
Time frame: At Month 12
Stage 1 mUC Cohorts: Duration of Response (DOR)
DOR was defined as the time from the first occurrence of a documented OR (CR or PR) during Stage 1 to PD or death from any cause during Stage 1, whichever occurred first, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median DOR.
Time frame: From first occurrence of a documented OR to PD or death from any cause, whichever occurred first (up to 61.5 months)
Stage 1 mUC Cohorts: Disease Control Rate (DCR)
DCR was defined as percentage of participants with stable disease for ≥ 18 weeks or an OR (CR or PR) during Stage 1, as determined by the investigator according to RECIST v1.1. SD was defined as neither sufficient shrinkage of target lesions to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. Percentages have been rounded off.
Time frame: Up to 61.5 months
Stages 1 and 2 mUC Cohorts: Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Stage 1: Up to 62.1 months; Stage 2: Up to 18.3 months
Stage 2 mUC [Atezo + EV Cohort]: Serum Concentration of Atezolizumab at Specified Timepoints
Time frame: Predose: Day 1 of Cycles 1, 2 and 4; 30 minutes postdose: Day 1 Cycle 1
Stage 2 mUC [Atezo + EV Cohort]: Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab
Participants were considered to be treatment-emergent ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following atezolizumab exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
Time frame: Up to approximately 18.3 months
MIBC Cohorts: Landmark Recurrence-free Survival (RFS) Rate
Landmark RFS was defined as the percentage of participants who were alive without disease recurrence at specified timepoints following surgery. RFS was defined as the time from Day 1 in the first cycle after surgery to the first documented recurrence of disease or death from any cause. RFS rates at the specified landmark timepoints were estimated using the K-M method.
Time frame: At Months 12, 18, and 24
MIBC Cohorts: Landmark Event-free Survival (EFS) Rate
Landmark EFS was defined as the percentage of participants who were alive without experiencing a predefined event at specified timepoints. EFS was defined as the time from randomization to any of the following events, whichever occurred first: PD that precludes surgery, as assessed by the investigator; local or distant disease recurrence; or death from any cause. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. EFS rates at the specified landmark timepoints were estimated using the K-M method.
Time frame: At Months 12, 18, and 24
MIBC Cohorts: Landmark OS Rate
Landmark OS was defined as the percentage of participants who were alive at specified timepoints. OS was defined as the time from randomization to death from any cause. OS rates at the specified landmark timepoints were estimated using the K-M method.
Time frame: At Months 12, 18, and 24
MIBC Cohorts: Number of Participants With AEs
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Up to 17.8 months
A total of 272 participants with muscle-invasive bladder cancer (MIBC) or locally advanced or metastatic urothelial carcinoma (mUC) who had progressed during or following a platinum-containing regimen took part in the study across 7 countries from 01 June 2019 to 22 December 2025.
| Milestone | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira | Stage 2 mUC Cohort: Atezo + EV | Stage 2 mUC Cohort: Atezo + SG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 30 | 15 | 16 | 15 | 12 | 15 | 31 | 15 | 6 | 11 | 23 | 47 | 18 | 18 | 0 | 0 |
| Safety-evaluable (se) population | 29 | 15 | 15 | 15 | 12 | 15 | 30 | 15 | 6 | 11 | 23 | 46 | 18 | 17 | 0 | 0 |
| Completed | 28 | 12 | 15 | 13 | 11 | 13 | 27 | 15 | 5 | 9 | 20 | 41 | 16 | 15 | 0 | 0 |
| Not completed | 2 | 3 | 1 | 2 | 1 | 2 | 4 | 0 | 1 | 2 | 3 | 6 | 2 | 3 | 0 | 0 |
| Withdrew: Death | 1 | 3 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 4 | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira | Stage 2 mUC Cohort: Atezo + EV | Stage 2 mUC Cohort: Atezo + SG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 15 |
| Se population | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 15 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira | Stage 2 mUC Cohort: Atezo + EV | Stage 2 mUC Cohort: Atezo + SG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 17 | 11 | 13 | 8 | 9 | 13 | 21 | 11 | 5 | 9 | 20 | 41 | 16 | 15 | 15 | 11 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 7 | 5 | 5 | 0 | 0 |
| Not completed | 17 | 11 | 13 | 8 | 9 | 13 | 21 | 11 | 5 | 6 | 17 | 34 | 11 | 10 | 15 | 11 |
| Withdrew: Reason not specified | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 1 |
| Withdrew: Death | 12 | 10 | 8 | 6 | 7 | 8 | 16 | 10 | 1 | 1 | 7 | 13 | 3 | 1 | 11 | 9 |
| Withdrew: Arm terminated by sponsor | 0 | 1 | 3 | 1 | 2 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 2 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 4 | 4 | 8 | 10 | 7 | 9 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PFS after randomization was defined as the time from randomization to the first occurrence of disease progression (PD) or death from any cause, whichever occurred first in Stage 1, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. PFS for participants with no documented PD or death was censored at the day of the last tumor assessment. Kaplan-Meier (K-M) method was used to estimate the median PFS.
| months | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ |
|---|---|---|---|---|---|---|---|---|
| Stage 1 mUC Cohorts: Progression-free Survival (PFS) After Randomization | 6.05 (3.52 to 10.18) | 4.47 (3.45 to 6.24) | 2.32 (1.97 to 10.51) | 2.23 (2.00 to 2.99) | 3.06 (2.10 to 14.32) | 3.48 (2.14 to 8.28) | 3.14 (2.10 to 4.86) | 4.07 (2.27 to 8.34) |
OS after randomization was defined as the time from randomization to death from any cause. Data for participants who had not died were censored at the last date they were known to be alive. K-M method was used to estimate the median OS.
| months | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ |
|---|---|---|---|---|---|---|---|---|
| Stage 1 mUC Cohorts: Overall Survival (OS) After Randomization | 18.79 (10.64 to 31.54) | 6.83 (5.62 to 10.68) | 21.82 (7.20 to NA) | 8.57 (5.16 to 35.45) | 7.33 (4.34 to 16.66) | 14.55 (8.25 to NA) | 12.32 (4.40 to 34.86) | 6.28 (5.13 to 19.88) |
OS rate at Month 12 was defined as percentage of participants who did not experience death from any cause at the specified timepoint. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate OS rate. Percentages have been rounded off.
| percentage of participants | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ |
|---|---|---|---|---|---|---|---|---|
| Stage 1 mUC Cohorts: OS Rate at Month 12 | 64.77 (47.15 to 82.39) | 26.67 (4.29 to 49.05) | 61.90 (35.56 to 88.25) | 39.16 (12.54 to 65.78) | 36.36 (7.94 to 64.79) | 61.90 (35.56 to 88.25) | 52.94 (34.95 to 70.93) | 40.00 (15.21 to 64.79) |
DOR was defined as the time from the first occurrence of a documented OR (CR or PR) during Stage 1 to PD or death from any cause during Stage 1, whichever occurred first, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median DOR.
| months | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ |
|---|---|---|---|---|---|---|---|---|
| Stage 1 mUC Cohorts: Duration of Response (DOR) | 32.16 (6.24 to NA) | 8.66 (4.07 to NA) | NA (8.34 to NA) | 13.11 (NA to NA) | NA (NA to NA) | 21.42 (NA to NA) | 42.74 (21.62 to NA) | 11.43 (6.24 to NA) |
DCR was defined as percentage of participants with stable disease for ≥ 18 weeks or an OR (CR or PR) during Stage 1, as determined by the investigator according to RECIST v1.1. SD was defined as neither sufficient shrinkage of target lesions to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. Percentages have been rounded off.
| percentage of participants | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ |
|---|---|---|---|---|---|---|---|---|
| Stage 1 mUC Cohorts: Disease Control Rate (DCR) | 48.3 (29.45 to 67.47) | 40.0 (16.34 to 67.71) | 26.7 (7.79 to 55.10) | 13.3 (1.66 to 40.46) | 25.0 (5.49 to 57.19) | 33.3 (11.82 to 61.62) | 30.0 (14.73 to 49.40) | 26.7 (7.79 to 55.10) |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| Participants | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ | Stage 2 mUC Cohort: Atezo + EV | Stage 2 mUC Cohort: Atezo + SG |
|---|---|---|---|---|---|---|---|---|---|---|
| Stages 1 and 2 mUC Cohorts: Number of Participants With Adverse Events (AEs) | 29 | 15 | 14 | 15 | 12 | 15 | 30 | 14 | 15 | 15 |
| micrograms per milliliter (µg/mL) | Stage 2 mUC Cohort: Atezo + EV |
|---|---|
| Predose: Cycle 1 Day 1 | 107 ± 60.1 |
| 30 min Postdose: Cycle 1 Day 1 | 390 ± 25.3 |
| Predose: Cycle 2 Day 1 | 105 ± 57.1 |
| Predose: Cycle 4 Day 1 | 121 ± 43.4 |
Participants were considered to be treatment-emergent ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following atezolizumab exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
| Participants | Stage 2 mUC Cohort: Atezo + EV |
|---|---|
| Stage 2 mUC [Atezo + EV Cohort]: Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab | 5 |
Landmark RFS was defined as the percentage of participants who were alive without disease recurrence at specified timepoints following surgery. RFS was defined as the time from Day 1 in the first cycle after surgery to the first documented recurrence of disease or death from any cause. RFS rates at the specified landmark timepoints were estimated using the K-M method.
| percentage of participants | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira |
|---|---|---|---|---|---|---|
| Month 12 | 100.00 (100.00 to 100.00) | 66.67 (28.95 to 100.00) | 81.82 (59.03 to 100.00) | 68.00 (49.71 to 86.29) | 80.00 (55.21 to 100.00) | 100.00 (100.00 to 100.00) |
| Month 18 | NA (NA to NA) | 66.67 (28.95 to 100.00) | 68.18 (37.26 to 99.10) | 63.47 (44.36 to 82.57) | 80.00 (55.21 to 100.00) | 91.67 (76.03 to 100.00) |
| Month 24 | NA (NA to NA) | 66.67 (28.95 to 100.00) | 68.18 (37.26 to 99.10) | 57.70 (37.26 to 78.14) | 70.00 (41.60 to 98.40) | 81.48 (58.08 to 100.00) |
Landmark EFS was defined as the percentage of participants who were alive without experiencing a predefined event at specified timepoints. EFS was defined as the time from randomization to any of the following events, whichever occurred first: PD that precludes surgery, as assessed by the investigator; local or distant disease recurrence; or death from any cause. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. EFS rates at the specified landmark timepoints were estimated using the K-M method.
| percentage of participants | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira |
|---|---|---|---|---|---|---|
| Month 12 | 83.33 (53.51 to 100.00) | 75.00 (44.99 to 100.00) | 73.68 (53.88 to 93.48) | 61.13 (46.23 to 76.04) | 59.58 (36.21 to 82.96) | 92.86 (79.37 to 100.00) |
| Month 18 | 83.33 (53.51 to 100.00) | 75.00 (44.99 to 100.00) | 60.79 (37.72 to 83.86) | 56.24 (41.06 to 71.42) | 59.58 (36.21 to 82.96) | 85.12 (66.05 to 100.00) |
| Month 24 | 83.33 (53.51 to 100.00) | 75.00 (44.99 to 100.00) | 45.59 (20.45 to 70.73) | 49.32 (33.23 to 65.42) | 52.96 (28.85 to 77.07) | 85.12 (66.05 to 100.00) |
Landmark OS was defined as the percentage of participants who were alive at specified timepoints. OS was defined as the time from randomization to death from any cause. OS rates at the specified landmark timepoints were estimated using the K-M method.
| percentage of participants | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira |
|---|---|---|---|---|---|---|
| Month 12 | 83.33 (53.51 to 100.00) | 88.89 (68.36 to 100.00) | 76.22 (57.95 to 94.50) | 75.01 (62.18 to 87.84) | 77.78 (58.57 to 96.98) | 93.75 (81.89 to 100.00) |
| Month 18 | 83.33 (53.51 to 100.00) | 88.89 (68.36 to 100.00) | 64.88 (43.59 to 86.17) | 67.98 (54.10 to 81.86) | 72.22 (51.53 to 92.91) | 93.75 (81.89 to 100.00) |
| Month 24 | 83.33 (53.51 to 100.00) | 88.89 (68.36 to 100.00) | 58.39 (35.75 to 81.04) | 61.83 (46.77 to 76.88) | 72.22 (51.53 to 92.91) | 87.50 (71.30 to 100.00) |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| Participants | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira |
|---|---|---|---|---|---|---|
| MIBC Cohorts: Number of Participants With AEs | 6 | 11 | 23 | 45 | 18 | 17 |
ORR was defined as the percentage of participants with an objective response (OR), characterized by a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart during Stage 1, as determined by the investigator per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). CR was defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.
| percentage of participants | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ |
|---|---|---|---|---|---|---|---|---|
| Stage 1 mUC Cohorts: Objective Response Rate (ORR) | 27.6 (12.73 to 47.24) | 26.7 (7.79 to 55.10) | 26.7 (7.79 to 55.10) | 6.7 (0.17 to 31.95) | 16.7 (2.09 to 48.41) | 6.7 (0.17 to 31.95) | 20.0 (7.71 to 38.57) | 20.0 (4.33 to 48.09) |
pCR was defined as the percentage of participants with an absence of residual invasive cancer of the complete resected specimen. Percentages have been rounded off.
| percentage of participants | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira |
|---|---|---|---|---|---|---|
| MIBC Cohorts: Pathological Complete Response (pCR) | 66.7 (22.28 to 95.67) | 27.3 (6.02 to 60.97) | 21.7 (7.46 to 43.70) | 20.0 (9.58 to 34.60) | 27.8 (9.69 to 53.48) | 23.5 (6.81 to 49.90) |
Collected over All AEs: Stage 1 mUC cohorts: Up to 62.1 months; Stage 2 mUC cohorts: Up to 18.3 months; MIBC cohorts: Up to 17.8 months All-cause mortality: Stage 1 & Stage 2 mUC cohorts: Up to 69.1 months; MIBC cohorts: Up to 42.2 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1 mUC Cohort: Atezo (Control) | 13/30 (43.3%) | 11/29 (37.9%) | 29/29 (100%) |
| Stage 1 mUC Cohort: Atezo + EV | 13/15 (86.7%) | 9/15 (60%) | 14/15 (93.3%) |
| Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | 8/16 (50%) | 8/15 (53.3%) | 14/15 (93.3%) |
| Stage 1 mUC Cohort: Atezo + Nira | 8/15 (53.3%) | 7/15 (46.7%) | 15/15 (100%) |
| Stage 1 mUC Cohort: Atezo + RO7122290 | 7/12 (58.3%) | 9/12 (75%) | 11/12 (91.7%) |
| Stage 1 Cohort 1 mUC Atezo+SG | 9/15 (60%) | 9/15 (60%) | 14/15 (93.3%) |
| Stage 1 mUC Cohort: Atezo + Tira | 19/31 (61.3%) | 12/30 (40%) | 30/30 (100%) |
| Stage 1 mUC Cohort: Atezo + TCZ | 10/15 (66.7%) | 8/15 (53.3%) | 14/15 (93.3%) |
| Stage 1 MIBC Cohort 1: Atezo (Control) | 1/6 (16.7%) | 5/6 (83.3%) | 6/6 (100%) |
| Stage 1 MIBC Cohort 1: Atezo + Tira | 2/11 (18.2%) | 6/11 (54.5%) | 11/11 (100%) |
| Stage 1 MIBC Cohort 2: Atezo (Control) | 8/23 (34.8%) | 14/23 (60.9%) | 22/23 (95.7%) |
| Stage 1 MIBC Cohort 2: Atezo + Tira | 17/47 (36.2%) | 35/46 (76.1%) | 41/46 (89.1%) |
| Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | 5/18 (27.8%) | 10/18 (55.6%) | 18/18 (100%) |
| Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira | 2/18 (11.1%) | 10/17 (58.8%) | 16/17 (94.1%) |
| Stage 2 mUC Cohort: Atezo + EV | 11/15 (73.3%) | 8/15 (53.3%) | 15/15 (100%) |
| Stage 2 mUC Cohort: Atezo + SG | 12/15 (80%) | 10/15 (66.7%) | 15/15 (100%) |
| Event | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 Cohort 1 mUC Atezo+SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira | Stage 2 mUC Cohort: Atezo + EV | Stage 2 mUC Cohort: Atezo + SG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 2/29 | 1/15 | 1/15 | 0/15 | 0/12 | 1/15 | 1/30 | 1/15 | 1/6 | 4/11 | 4/23 | 8/46 | 1/18 | 6/17 | 2/15 | 1/15 |
| Acute kidney injuryRenal and urinary disorders | 0/29 | 0/15 | 0/15 | 1/15 | 0/12 | 1/15 | 0/30 | 1/15 | 2/6 | 0/11 | 1/23 | 9/46 | 1/18 | 1/17 | 0/15 | 1/15 |
| SepsisInfections and infestations | 0/29 | 0/15 | 1/15 | 1/15 | 0/12 | 2/15 | 0/30 | 0/15 | 0/6 | 3/11 | 3/23 | 4/46 | 2/18 | 0/17 | 1/15 | 3/15 |
| PyrexiaGeneral disorders | 1/29 | 2/15 | 1/15 | 0/15 | 0/12 | 0/15 | 2/30 | 0/15 | 0/6 | 0/11 | 0/23 | 1/46 | 0/18 | 2/17 | 0/15 | 3/15 |
| Acute coronary syndromeCardiac disorders | 0/29 | 0/15 | 0/15 | 0/15 | 0/12 | 0/15 | 0/30 | 0/15 | 1/6 | 0/11 | 0/23 | 0/46 | 0/18 | 0/17 | 0/15 | 0/15 |
| Enterovesical fistulaGastrointestinal disorders | 0/29 | 0/15 | 0/15 | 0/15 | 0/12 | 0/15 | 0/30 | 0/15 | 1/6 | 0/11 | 0/23 | 0/46 | 0/18 | 0/17 | 0/15 | 0/15 |
| EpilepsyNervous system disorders | 0/29 | 0/15 | 0/15 | 0/15 | 0/12 | 0/15 | 0/30 | 0/15 | 1/6 | 0/11 | 0/23 | 0/46 | 0/18 | 0/17 | 0/15 | 0/15 |
| Urinary retentionRenal and urinary disorders | 0/29 | 0/15 | 0/15 | 0/15 | 0/12 | 0/15 | 0/30 | 0/15 | 1/6 | 0/11 | 0/23 | 0/46 | 0/18 | 0/17 | 0/15 | 0/15 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/29 | 1/15 | 0/15 | 0/15 | 2/12 | 0/15 | 0/30 | 1/15 | 0/6 | 0/11 | 0/23 | 0/46 | 0/18 | 0/17 | 1/15 | 0/15 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/29 | 0/15 | 0/15 | 0/15 | 0/12 | 2/15 | 0/30 | 0/15 | 0/6 | 0/11 | 0/23 | 0/46 | 0/18 | 0/17 | 0/15 | 1/15 |
| Event | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 Cohort 1 mUC Atezo+SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira | Stage 2 mUC Cohort: Atezo + EV | Stage 2 mUC Cohort: Atezo + SG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 7/29 | 5/15 | 4/15 | 2/15 | 4/12 | 7/15 | 10/30 | 3/15 | 1/6 | 9/11 | 4/23 | 16/46 | 2/18 | 6/17 | 5/15 | 4/15 |
| AnaemiaBlood and lymphatic system disorders | 6/29 | 6/15 | 8/15 | 7/15 | 1/12 | 10/15 | 3/30 | 1/15 | 1/6 | 4/11 | 6/23 | 16/46 | 10/18 | 10/17 | 4/15 | 7/15 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/29 | 2/15 | 0/15 | 0/15 | 0/12 | 6/15 | 0/30 | 0/15 | 2/6 | 0/11 | 0/23 | 2/46 | 1/18 | 1/17 | 9/15 | 6/15 |
| NauseaGastrointestinal disorders | 1/29 | 4/15 | 2/15 | 4/15 | 1/12 | 7/15 | 10/30 | 0/15 | 1/6 | 1/11 | 4/23 | 11/46 | 9/18 | 10/17 | 4/15 | 6/15 |
| Decreased appetiteMetabolism and nutrition disorders | 7/29 | 8/15 | 4/15 | 4/15 | 4/12 | 5/15 | 7/30 | 1/15 | 1/6 | 1/11 | 3/23 | 11/46 | 6/18 | 3/17 | 6/15 | 1/15 |
| RashSkin and subcutaneous tissue disorders | 5/29 | 3/15 | 1/15 | 2/15 | 4/12 | 4/15 | 6/30 | 1/15 | 0/6 | 5/11 | 2/23 | 17/46 | 3/18 | 6/17 | 8/15 | 0/15 |
| FatigueGeneral disorders | 6/29 | 7/15 | 5/15 | 5/15 | 3/12 | 3/15 | 14/30 | 2/15 | 2/6 | 2/11 | 8/23 | 20/46 | 9/18 | 7/17 | 6/15 | 3/15 |
| Blood creatinine increasedInvestigations | 6/29 | 2/15 | 3/15 | 4/15 | 1/12 | 3/15 | 4/30 | 2/15 | 3/6 | 2/11 | 3/23 | 9/46 | 5/18 | 3/17 | 2/15 | 1/15 |
| Urinary tract infectionInfections and infestations | 5/29 | 2/15 | 6/15 | 1/15 | 1/12 | 3/15 | 7/30 | 3/15 | 1/6 | 3/11 | 7/23 | 14/46 | 4/18 | 8/17 | 4/15 | 2/15 |
| ConstipationGastrointestinal disorders | 3/29 | 5/15 | 2/15 | 3/15 | 0/12 | 6/15 | 8/30 | 5/15 | 0/6 | 1/11 | 6/23 | 12/46 | 8/18 | 5/17 | 4/15 | 2/15 |
All randomized population included all participants randomized to each treatment arm.
| Age, Customized(Participants) | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira | Stage 2 mUC Cohort: Atezo + EV | Stage 2 mUC Cohort: Atezo + SG | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1 — Adults (18-64 years) | 8 | 6 | 4 | 6 | 4 | 6 | 11 | 9 | 2 | 2 | 5 | 3 | 5 | 8 | — | — | 79 |
| Stage 1 — From 65-84 years | 21 | 9 | 12 | 8 | 8 | 9 | 20 | 6 | 4 | 9 | 18 | 44 | 13 | 10 | — | — | 191 |
| Stage 1 — 85 years and over | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 2 |
| Stage 2 — Adults (18-64 years) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 5 | 3 | 8 |
| Stage 2 — From 65-84 years | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 10 | 11 | 21 |
| Stage 2 — 85 years and over | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira | Stage 2 mUC Cohort: Atezo + EV | Stage 2 mUC Cohort: Atezo + SG | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1 — Female | 5 | 3 | 6 | 2 | 4 | 3 | 6 | 4 | 1 | 2 | 5 | 10 | 2 | 3 | — | — | 56 |
| Stage 1 — Male | 25 | 12 | 10 | 13 | 8 | 12 | 25 | 11 | 5 | 9 | 18 | 37 | 16 | 15 | — | — | 216 |
| Stage 2 — Female | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4 | 4 | 8 |
| Stage 2 — Male | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 11 | 11 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira | Stage 2 mUC Cohort: Atezo + EV | Stage 2 mUC Cohort: Atezo + SG | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1 — Hispanic or Latino | 1 | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 2 | 0 | 0 | 2 | 2 | 4 | — | — | 16 |
| Stage 1 — Not Hispanic or Latino | 27 | 15 | 11 | 12 | 10 | 12 | 25 | 14 | 4 | 10 | 23 | 44 | 16 | 14 | — | — | 237 |
| Stage 1 — Unknown or Not Reported | 2 | 0 | 5 | 3 | 1 | 1 | 4 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | — | — | 19 |
| Stage 2 — Hispanic or Latino | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Stage 2 — Not Hispanic or Latino | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 14 | 14 | 28 |
| Stage 2 — Unknown or Not Reported | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Stage 1 mUC Cohort: Atezo (Control) | Stage 1 mUC Cohort: Atezo + EV | Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | Stage 1 mUC Cohort: Atezo + Nira | Stage 1 mUC Cohort: Atezo + RO7122290 | Stage 1 mUC Cohort: Atezo + SG | Stage 1 mUC Cohort: Atezo + Tira | Stage 1 mUC Cohort: Atezo + TCZ | Stage 1 MIBC Cohort 1: Atezo (Control) | Stage 1 MIBC Cohort 1: Atezo + Tira | Stage 1 MIBC Cohort 2: Atezo (Control) | Stage 1 MIBC Cohort 2: Atezo + Tira | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira | Stage 2 mUC Cohort: Atezo + EV | Stage 2 mUC Cohort: Atezo + SG | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1 — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Stage 1 — Asian | 8 | 4 | 5 | 2 | 2 | 7 | 9 | 6 | 1 | 0 | 0 | 7 | 0 | 0 | — | — | 51 |
| Stage 1 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | — | — | 1 |
| Stage 1 — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | — | — | 3 |
| Stage 1 — White | 20 | 10 | 6 | 10 | 8 | 7 | 16 | 8 | 5 | 10 | 22 | 36 | 17 | 18 | — | — | 193 |
| Stage 1 — More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Stage 1 — Unknown or Not Reported | 2 | 1 | 5 | 3 | 2 | 1 | 6 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | — | — | 24 |
| Stage 2 — American Indian or Alaska Native | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Stage 2 — Asian | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4 | 3 | 7 |
| Stage 2 — Native Hawaiian or Other Pacific Islander | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Stage 2 — Black or African American | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Stage 2 — White | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 10 | 11 | 21 |
| Stage 2 — More than one race | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Stage 2 — Unknown or Not Reported | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Jun 2019 to primary completion in Oct 2025, 76 months.
Results were first posted in Aug 2026, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Enfortumab vedotin · Niraparib · Magrolimab · Tiragolumab · Sacituzumab govitecan · Tocilizumab · Cisplatin · Gemcitabine
Carcinoma, Transitional Cell →